Cancer Research Technology
Log in Register
Menu

Anti-Lewis Y [69/229]

Invented by Prof Lindy Durrant at University of Nottingham

Info

Catalogue Number 153393
Applications FACS IHC
Antigen/Gene or Protein Targets Lewis Y
Reactivity Human
Relevance MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.
Host Mouse
Immunogen Colonic Adenoma membranes
Subclass IgG3 kappa
Myeloma Used P3/NS1/1-Ag4.1
Research Area Cancer, Epigenetics & Nuclear Signalling

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.

Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.

Europe PMC ID: 23408949


Add a reference

References: 2 entries

Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.

Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.


Add a reference